Physician profile
Thomas Kehn
NPI 1215990254
$2,859.40
in general payments reported to CMS, 2019-2025
36 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $150 · 2021: $325 · 2022: $600 · 2023: $351 · 2024: $609 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $354.65 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Glaukos Corporation | $209.75 | 2019-2025 | Idosetr, Photrexa |
| Tarsus Pharmaceuticals, INC. | $195.25 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $183.41 | 2022-2024 | Tyrvaya |
| Rxsight INC | $179.76 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $178.76 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $153.57 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $146.63 | 2020-2023 | |
| Astellas Pharma US INC | $97.09 | 2024 | Izervay |
| Biotissue Holdings INC. | $91.03 | 2021-2023 | |
| Thea Pharma INC. | $83.66 | 2022-2024 | Iyuzeh |
| Dompe US, INC. | $81.55 | 2024-2025 | Oxervate |
| New World Medical,INC. | $78.47 | 2021-2023 | |
| Mallinckrodt Enterprises LLC | $75.10 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $73.54 | 2019-2023 | Tecnis Iol, Healon Duet Pro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $61.79 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $61.54 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $59.77 | 2021-2022 | |
| Abbvie INC. | $54.34 | 2023-2025 | |
| Tearlab Corp | $46.22 | 2020 | |
| Eyevance Pharmaceuticals LLC | $42.64 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $36.34 | 2019-2021 | |
| Akorn, INC. | $34.54 | 2019 | |
| Rayner Intraocular Lenses Limited | $29.75 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.77 | 2020 | |
| Shire North American Group INC | $28.68 | 2019 | |
| Ocular Therapeutix, INC. | $27.04 | 2019-2021 | |
| Amgen INC. | $24.37 | 2024 | Tepezza |
| Lumenis, INC | $23.22 | 2021 | |
| Lensar, INC. | $19.35 | 2025 | Lensar Laser System |
| Akorn Operating Company LLC | $17.92 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $17.89 | 2024 | Forum |
| Kala Pharmaceuticals, INC. | $16.99 | 2019 | |
| Omeros Corporation | $16.64 | 2020 | |
| Sight Sciences, INC. | $15.11 | 2021 | |
| Ani Pharmaceuticals, INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.